N-Methylformamide in advanced squamous cancer of the uterine cervix: An Eastern Cooperative Oncology Group phase II trial

Lakshmi Rajdev, Zi Fan Yu, Scott Wadler, Edie Weller, S. Benham Kahn, Douglass Tormey, Roland Skeel, Peter H. Wiernik

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25%, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30% (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.

Original languageEnglish (US)
Pages (from-to)233-237
Number of pages5
JournalInvestigational New Drugs
Volume19
Issue number3
DOIs
StatePublished - 2001

Fingerprint

methylformamide
Uterine Cervical Neoplasms
Cervix Uteri
Vomiting
Squamous Cell Carcinoma
Drug Approval
Survival Analysis
Aspartate Aminotransferases

Keywords

  • N-Methylformamide
  • Squamous cell carcinoma
  • Uterine cervix

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

N-Methylformamide in advanced squamous cancer of the uterine cervix : An Eastern Cooperative Oncology Group phase II trial. / Rajdev, Lakshmi; Yu, Zi Fan; Wadler, Scott; Weller, Edie; Kahn, S. Benham; Tormey, Douglass; Skeel, Roland; Wiernik, Peter H.

In: Investigational New Drugs, Vol. 19, No. 3, 2001, p. 233-237.

Research output: Contribution to journalArticle

Rajdev, Lakshmi ; Yu, Zi Fan ; Wadler, Scott ; Weller, Edie ; Kahn, S. Benham ; Tormey, Douglass ; Skeel, Roland ; Wiernik, Peter H. / N-Methylformamide in advanced squamous cancer of the uterine cervix : An Eastern Cooperative Oncology Group phase II trial. In: Investigational New Drugs. 2001 ; Vol. 19, No. 3. pp. 233-237.
@article{dc93dec4a89840c4adefd75a4af7ff06,
title = "N-Methylformamide in advanced squamous cancer of the uterine cervix: An Eastern Cooperative Oncology Group phase II trial",
abstract = "Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25{\%}, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30{\%} (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.",
keywords = "N-Methylformamide, Squamous cell carcinoma, Uterine cervix",
author = "Lakshmi Rajdev and Yu, {Zi Fan} and Scott Wadler and Edie Weller and Kahn, {S. Benham} and Douglass Tormey and Roland Skeel and Wiernik, {Peter H.}",
year = "2001",
doi = "10.1023/A:1010672618269",
language = "English (US)",
volume = "19",
pages = "233--237",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - N-Methylformamide in advanced squamous cancer of the uterine cervix

T2 - An Eastern Cooperative Oncology Group phase II trial

AU - Rajdev, Lakshmi

AU - Yu, Zi Fan

AU - Wadler, Scott

AU - Weller, Edie

AU - Kahn, S. Benham

AU - Tormey, Douglass

AU - Skeel, Roland

AU - Wiernik, Peter H.

PY - 2001

Y1 - 2001

N2 - Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25%, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30% (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.

AB - Purpose: Preclinical and clinical data support the study of polar-planar compounds such as N-Methylformamide (NMF) in advanced squamous cell carcinoma of the uterine cervix (SCC). This phase II trial sought to determine the efficacy and toxicities of NMF in patients with advanced SCC. Patients and methods: Eligibility for this trial required bidimensionally measurable squamous or adenosquamous cell cancer of the uterine cervix incurable by surgery or radiation therapy, ECOG performance status of ≤2, no prior NMF and no more than one prior chemotherapy regimen. Patients received NMF at 2000 mg/m 2 intravenously over 15-30 minutes days 1, 8 and 15. The cycle was repeated every 42 days. A single dose escalation of 25%, 500 mg/m 2 was made after the first cycle if the toxicities did not exceed grade I for hepatic toxicity and grade II for nausea and vomiting. Results: From July 1987 through September 1998, 21 patients with advanced squamous cell carcinoma of the uterine cervix were entered on study. Two patients were ineligible because there was no pretreatment SGOT on one and the other deteriorated prior to drug approval. Therefore, 19 patients were include in the analysis of response and survival. Four were inevaluable, three due to inappropriate tumor evaluation and one secondary to grade III vomiting, who went off study. These patients were included in the denominator while computing the results. There were 2 deaths, one due to pulmonary hemorrhage from perforation during central venous insertion and one due to disease. 30% (6/19) patients had toxicities, Eastern Cooperative Oncology Group (ECOG) grade III or higher and 2 of these patients suffered multiple grade III toxicities. There were no complete or partial responses. Conclusion: In this population, NMF in the dose and schedule employed exhibited no clinical activity.

KW - N-Methylformamide

KW - Squamous cell carcinoma

KW - Uterine cervix

UR - http://www.scopus.com/inward/record.url?scp=0034844521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034844521&partnerID=8YFLogxK

U2 - 10.1023/A:1010672618269

DO - 10.1023/A:1010672618269

M3 - Article

C2 - 11561680

AN - SCOPUS:0034844521

VL - 19

SP - 233

EP - 237

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -